Nanoscale-based delivery of RNAi for cancer therapy

DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases

Volumn , Issue , 2013, Pages 349-372

  Scomparin, Anna ^a   Tiram, Galia ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Delivery systems; Nanomedicines; Oligonucleotides; Personalized cancer therapy

Indexed keywords

CELL MEMBRANES; CONTROLLED DRUG DELIVERY; DISEASES; GENES; LIPOSOMES; MEDICAL NANOTECHNOLOGY; NANOTECHNOLOGY; NUCLEIC ACIDS; OLIGONUCLEOTIDES; ONCOLOGY; PROTEINS; RNA; TISSUE;

CANCER THERAPY; CELLULAR MEMBRANES; DELIVERY SYSTEMS; DRUG DELIVERY SYSTEM; ENHANCED PERMEABILITY AND RETENTION EFFECTS; PHYSIOLOGICAL CONDITION; PROTEIN INTERACTION NETWORKS; THERAPEUTIC AGENTS;

TARGETED DRUG DELIVERY;

EID: 84955203395     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-36853-0_14     Document Type: Chapter

References (121)

1. Abrams MT, Koser ML, Seitzer J et al (2010) Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 18: 171-180
2. Aleku M, Schulz P, Keil O et al (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68: 9788-9798
3. Amarzguioui M, Rossi JJ, Kim D (2005) Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 579: 5974-5981
4. Arima H, Yoshimatsu A, Ikeda H et al (2012) Folate-PEG-appended dendrimer conjugate with alpha-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. Mol Pharm 9: 2591-2604
5. Asahina H, Yamazaki K, Kinoshita I et al (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95: 998-1004
6. Behr JP, Demeneix B, Loeffler JP et al (1989) Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA 86: 6982-6986
7. Bologna JC, Dorn G, Natt F et al (2003) Linear polyethylenimine as a tool for comparative studies of antisense and short double-stranded RNA oligonucleotides. Nucleosides Nucleotides Nucleic Acids 22: 1729-1731
8. Boussif O, Lezoualc’h F, Zanta MA et al (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301
9. Buhleier E, Wehner W, Vogtle F (1978) "Cascade” and "Nonskid-Chain-like” syntheses of molecular cavity topologies. Synthesis 2: 155-158
10. Cervantes A, Alsina M, Tabernero J et al (2011) Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. In: ASCO annual meeting, Journal of Clinical Oncology, Chicago, IL
11. Chen H, Ma X, Li Z et al (2012) Functionalization of single-walled carbon nanotubes enables efficient intracellular delivery of siRNA targeting MDM2 to inhibit breast cancer cells growth. Biomed Pharmacother 66: 334-338
12. Choi JS, Lee EJ, Jang HS et al (2001) New cationic liposomes for gene transfer into mammalian cells with high efficiency and low toxicity. Bioconjug Chem 12: 108-113
13. Christie RJ, Matsumoto Y, Miyata K et al (2012) Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 6: 5174-5189
14. Dabkowska AP, Barlow DJ, Campbell RA et al (2012) Effect of helper lipids on the interaction of DNA with cationic lipid monolayers studied by specular neutron reflection. Biomacromolecules 13: 2391-2401
15. Daka A, Peer D (2012) RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 64: 1508-1521
16. Davidson BL, McCray PB Jr (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340
17. Davis ME, Zuckerman JE, Choi CH et al (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070
18. de Fougerolles A, Vornlocher HP, Maraganore J et al (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453
19. De Martimprey H, Bertrand JR, Malvy C et al (2010) New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm Res 27: 498-509
20. Derfus AM, Chen AA, Min DH et al (2007) Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem 18: 1391-1396
21. Dharmapuri S, Peruzzi D, Marra E et al (2011) Intratumor RNA interference of cell cycle genes slows down tumor progression. Gene Ther 18: 727-733
22. Dominska M, Dykxhoorn DM (2010) Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 123: 1183-1189
23. Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417
24. Emi N, Kidoaki S, Yoshikawa K et al (1997) Gene transfer mediated by polyarginine requires a formation of big carrier-complex of DNA aggregate. Biochem Biophys Res Commun 231: 421-424
25. Felgner PL, Gadek TR, Holm M et al (1987) Lipofection: a highly efficient, lipid-mediated DNAtransfection procedure. Proc Natl Acad Sci USA 84: 7413-7417
26. Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391: 806-811
27. Fischer W, Calderon M, Schulz A et al (2010) Dendritic polyglycerols with oligoamine shells show low toxicity and high siRNA transfection efficiency in vitro. Bioconjug Chem 21: 1744-1752
28. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
29. Fraley R, Subramani S, Berg P et al (1980) Introduction of liposome-encapsulated SV40 DNA into cells. J Biol Chem 255: 10431-10435
30. Futreal PA, Coin L, Marshall M et al (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183
31. Gao X, Huang L (1991) A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 179: 280-285
32. Gao H, Hui KM (2001) Synthesis of a novel series of cationic lipids that can act as efficient gene delivery vehicles through systematic heterocyclic substitution of cholesterol derivatives. Gene Ther 8: 855-863
33. Gunasekaran K, Nguyen TH, Maynard HD et al (2011) Conjugation of siRNA with comb-type PEG enhances serum stability and gene silencing efficiency. Macromol Rapid Commun 32: 654-659
34. Gunther M, Lipka J, Malek A et al (2011) Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 77: 438-449
35. Guo J, Ogier JR, Desgranges S et al (2012) Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 33: 7775-7784
36. Hafez IM, Maurer N, Cullis PR (2001) On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8: 1188-1196
37. Hannon GJ, Rossi JJ (2004) Unlocking the potential of the human genome with RNA interference. Nature 431: 371-378
38. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221
39. Hashimoto T, Kawazu K, Nagasaki T et al (2012) Quantitative comparison between poly(Larginine) and poly(L-lysine) at each step of polyplex-based gene transfection using a microinjection technique. Sci Technol Adv Mater 13: 9-15
40. Heel RC, Brogden RN, Speight TM et al (1978) Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16: 1-24
41. Herrero MA, Toma FM, Al-Jamal KT et al (2009) Synthesis and characterization of a carbon nanotube-dendron series for efficient siRNA delivery. J Am Chem Soc 131: 9843-9848
42. Howard KA (2009) Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv Drug Deliv Rev 61: 710-720
43. Huang HW, Chen FY, Lee MT (2004) Molecular mechanism of peptide-induced pores in membranes. Phys Rev Lett 92: 198304
44. Huang HY, Kuo WT, Chou MJ et al (2011) Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J Biomed Mater Res A 97: 330-338
45. Huh MS, Lee SY, Park S et al (2010) Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J Control Release 144: 134-143
46. Ilies MA, Johnson BH, Makori F et al (2005) Pyridinium cationic lipids in gene delivery: an in vitro and in vivo comparison of transfection efficiency versus a tetraalkylammonium congener. Arch Biochem Biophys 435: 217-226
47. Jain K, Kesharwani P, Gupta U et al (2010) Dendrimer toxicity: let’s meet the challenge. Int J Pharm 394: 122-142
48. Jeong JH, Mok H, Oh YK et al (2009) siRNA conjugate delivery systems. Bioconjug Chem 20: 5-14
49. Jevprasesphant R, Penny J, Jalal R et al (2003) The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 252: 263-266
50. Jin J, Bae KH, Yang H et al (2011) In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem 22: 2568-2572
51. Jung S, Lee SH, Mok H et al (2010) Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight. J Control Release 144: 306-313
52. Kam NW, Liu Z, Dai H (2005) Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 127: 12492-12493
53. Katas H, Alpar HO (2006) Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 115: 216-225
54. Kearns MD, Donkor AM, Savva M (2008) Structure-transfection activity studies of novel cationic cholesterol-based amphiphiles. Mol Pharm 5: 128-139
55. Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6: 376-385
56. Kim TI, Seo HJ, Choi JS et al (2004) PAMAM-PEG-PAMAM: novel triblock copolymer as a biocompatible and efficient gene delivery carrier. Biomacromolecules 5: 2487-2492
57. Kim HR, Kim IK, Bae KH et al (2008) Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm 5: 622-631
58. Kircheis R, Wightman L, Wagner E (2001) Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev 53: 341-358
59. Kirpotin DB, Drummond DC, Shao Y et al (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66: 6732-6740
60. Kolhatkar RB, Kitchens KM, Swaan PW et al (2007) Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem 18: 2054-2060
61. Krek A, Grun D, Poy MN et al (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495-500
62. Landen CN Jr, Chavez-Reyes A, Bucana C et al (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918
63. Lebleu B, Moulton HM, Abes R et al (2008) Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 60: 517-529
64. Lee SH, Mok H, Lee Y et al (2011a) Self-assembled siRNA-PLGA conjugate micelles for gene silencing. J Control Release 152: 152-158
65. Lee SH, Mok H, Park TG (2011b) Di- and triblock siRNA-PEG copolymers: PEG density effect of polyelectrolyte complexes on cellular uptake and gene silencing efficiency. Macromol Biosci 11: 410-418
66. Lee JY, Lee SH, Oh MH et al (2012a) Prolonged gene silencing by siRNA/chitosan-g-deoxycholic acid polyplexes loaded within biodegradable polymer nanoparticles. J Control Release 162: 407-413
67. Lee SJ, Huh MS, Lee SY et al (2012b) Tumor-homing poly-siRNA/glycol chitosan self-crosslinked nanoparticles for systemic siRNA delivery in cancer treatment. Angew Chem Int Ed Engl 51: 7203-7207
68. Li L, Shen Y (2009) Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Ther 9: 609-619
69. Liu P, Yu H, Sun Y et al (2012) A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 33: 4403-4412
70. Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E et al (2011) In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano 5: 9977-9983
71. Luten J, van Nostrum CF, De Smedt SC et al (2008) Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release 126: 97-110
72. Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 3: 1377-1397
73. Mao S, Sun W, Kissel T (2010) Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 62: 12-27
74. Matsumoto S, Christie RJ, Nishiyama N et al (2009) Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery. Biomacromolecules 10: 119-127
75. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392
76. Miller K, Erez R, Segal E et al (2009) Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 48: 2949-2954
77. Mok H, Lee SH, Park JW et al (2010) Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater 9: 272-278
78. Moschos SA, Jones SW, Perry MM et al (2007) Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 18: 1450-1459
79. Muller RH, Mader K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50: 161-177
80. Namgung R, Kim WJ (2012) A highly entangled polymeric nanoconstruct assembled by siRNA and its reduction-trigged siRNA release for gene silencing. Small 8: 3209-3219
81. Nishina K, Unno T, Uno Y et al (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 16: 734-740
82. Ofek P, Fischer W, Calderon M et al (2010) In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J 24: 3122-3134
83. Oishi M, Nagasaki Y, Itaka K et al (2005) Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc 127: 1624-1625
84. Olbrich C, Bakowsky U, Lehr CM et al (2001) Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release 77: 345-355
85. Ortiz Mellet C, Garcia Fernandez JM, Benito JM (2011) Cyclodextrin-based gene delivery systems. Chem Soc Rev 40: 1586-1608
86. Pangburn TO, Georgiou K, Bates FS et al (2012) Targeted polymersome delivery of siRNA induces cell death of breast cancer cells dependent upon Orai3 protein expression. Langmuir 28: 12816-12830
87. Parente RA, Nir S, Szoka FC Jr (1990) Mechanism of leakage of phospholipid vesicle contents induced by the peptide GALA. Biochemistry 29: 8720-8728
88. Pasqualini R, Koivunen E, Kain R et al (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60: 722-727
89. Patil YB, Swaminathan SK, Sadhukha T et al (2010) The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31: 358-365
90. Pierschbacher MD, Ruoslahti E (1984) Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc Natl Acad Sci USA 81: 5985-5988
91. Podesta JE, Al-Jamal KT, Herrero MA et al (2009) Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 5: 1176-1185
92. Raouane M, Desmaele D, Gilbert-Sirieix M et al (2011) Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J Med Chem 54: 4067-4076
93. Remy JS, Sirlin C, Vierling P et al (1994) Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjug Chem 5: 647-654
94. Ribas A, Kalinoski L, Heidel JD et al (2010) Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: results from a first-in-class phase I clinical trial. In: ASCO annual meeting, Chicago, IL
95. Rozema DB, Lewis DL, Wakefield DH et al (2007) Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 104: 12982-12987
96. Saranya N, Moorthi A, Saravanan S et al (2011) Chitosan and its derivatives for gene delivery. Int J Biol Macromol 48: 234-238
97. Segal E, Pan H, Ofek P et al (2009) Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 4: e5233
98. Semple SC, Harasym TO, Clow KA et al (2005) Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 312: 1020-1026
99. Semple SC, Akinc A, Chen J et al (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176
100. Seymour LW, Ferry DR, Anderson D et al (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668-1676
101. Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178
102. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458: 719-724
103. Strumberg D, Schultheis B, Traugott U et al (2012) Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 50: 76-78
104. Sun TM, Du JZ, Yao YD et al (2011) Simultaneous delivery of siRNA and paclitaxel via a "twoin-one” micelleplex promotes synergistic tumor suppression. ACS Nano 5: 1483-1494
105. Taratula O, Garbuzenko OB, Kirkpatrick P et al (2009) Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 140: 284-293
106. Tekmira (2012) http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID1/4700453
107. Tros de Ilarduya C, Sun Y, Duzgunes N (2010) Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 40: 159-170
108. Tsai LR, Chen MH, Chien CT et al (2011) A single-monomer derived linear-like PEI-co-PEG for siRNA delivery and silencing. Biomaterials 32: 3647-3653
109. Ulbrich K, Etrych T, Chytil P et al (2004) Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target 12: 477-489
110. Urban-Klein B, Werth S, Abuharbeid S et al (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12: 461-466
111. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726
112. Wang X, Ren J, Qu X (2008) Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells. ChemMedChem 3: 940-945
113. Wu GY, Wu CH (1988) Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochemistry 27: 887-892
114. Xia W, Wang P, Lin C et al (2012) Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo. J Control Release 157: 427-436
115. Xu Y, Szoka FC Jr (1996) Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35: 5616-5623
116. Xue HY, Wong HL (2011) Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 32: 2662-2672
117. York AW, Huang F, McCormick CL (2010) Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMAs-APMA) copolymers. Biomacromolecules 11: 505-514
118. Yu YH, Kim E, Park DE et al (2012) Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm 80: 268-273
119. Zelphati O, Szoka FC Jr (1996) Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 93: 11493-11498
120. Zhang JS, Liu F, Huang L (2005) Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 57: 689-698
121. Zhou J, Patel TR, Fu M et al (2012) Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33: 583-591